The Brugada syndrome: Diagnostic criteria and cellular mechanisms

European Heart Journal

Volumn 22, Issue 5, 2001, Pages 356-363

  Antzelevitch, C ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARRHYTHMOGENESIS; BRUGADA SYNDROME; CLINICAL EXAMINATION; CORRELATION FUNCTION; EDITORIAL; ELECTROCARDIOGRAM; EPICARDIUM; GENE MUTATION; HEART DEATH; HEART MUSCLE POTENTIAL; HUMAN; PRIORITY JOURNAL; SEX RATIO; ST SEGMENT; SUDDEN DEATH;

ELECTROCARDIOGRAPHY; GENETIC HETEROGENEITY; HUMANS; PHENOTYPE; VENTRICULAR FIBRILLATION;

EID: 0034932477     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2000.2461     Document Type: Editorial

References (32)

1. Mode of onset of malignant ventricular arrhythmias in idiopathic ventricular fibrillation
2. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter report
3. "Brugada" syndrome: Clinical data and suggested pathophysiological mechanism
4. The Brugada syndrome: Ionic basis and arrhythmia mechanisms
5. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men
6. Brugada syndrome and sudden cardiac death in children
7. What is the Brugada syndrome?
8. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts
9. Diagnosis and long-term follow-up of Brugada syndrome in patients with idiopathic ventricular fibrillation
10. Prevalence of the Brugada sign in idiopathic ventricular fibrillation and healthy controls
11. Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation
12. Cellular basis for the Brugada Syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation
13. Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome
14. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent
15. Electrophysiological characterization of SCN5A mutations causing long QT (E1784K) and Brugada (R1512W and R1432G) syndromes
16. A single Na(+) channel mutation causing both long-QT and Brugada syndromes
17. Mutations in the human cardiac sodium channel gene (SCN5A) in patients with Brugada syndrome
18. Cellular basis for the electrocardiographic J wave
19. The Brugada syndrome: Clinical, electrophysiological and genetic aspects
20. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome
21. Phase 2 reentry as a mechanism of initiation of circus movement reentry in canine epicardium exposed to simulated ischemia. The antiarrhythmic effects of 4-aminopyridine
22. Electrical heterogeneity in the heart: Physiological, pharmacological and clinical implications
23. Ion channels and ventricular arrhythmias. Cellular and ionic mechanisms underlying the Brugada syndrome
24. Brugada-like electrocardiographic pattern in a patient with a mediastinal tumor
25. Possible role of left ventricular programmed stimulation in Brugada syndrome
26. Differences in the electrophysiological response of canine ventricular subendocardium and subepicardium to acetylcholine and isoproterenol. A direct effect of acetylcholine in ventricular myocardium
27. Flecainide-induced arrhythmia in canine ventricular epicardium: Phase 2 Reentry?
28. Increased dispersion of repolarization time determined by monophasic action potentials in two patients with familial idiopathic ventricular fibrillation
29. Coexpression with beta(1)-subunit modifies the kinetics and fatty acid block of hH1(alpha) Na(+) channels
30. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenesis of human siderotic heart disease
31. Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: Clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms